1.Epidemiological study on the incidence of inflammatory bowel disease in Yinzhou District, Ningbo City from 2011 to 2020.
Bing Jie HE ; Zhi Ke LIU ; Peng SHEN ; Ye Xiang SUN ; Bin CHEN ; Si Yan ZHAN ; Hong Bo LIN
Journal of Peking University(Health Sciences) 2022;54(3):511-519
		                        		
		                        			OBJECTIVE:
		                        			To describe the distribution characteristics of inflammatory bowel disease among permanent residents in Yinzhou District, Ningbo City, and to understand the disease burden and development trend of inflammatory bowel disease in this area.
		                        		
		                        			METHODS:
		                        			Using the retrospective cohort design, we collected the registration information of all permanent residents in the residents' health files of the Yinzhou Regional Health Information Platform from 2010 to 2020, and used electronic medical records to follow up their inflammatory bowel disease visits. A one-year wash-out period was set, and the patients who were diagnosed with the primary diagnosis for the first time after one year of registration were re-garded as new cases. The incidence density and 95% confidence interval (CI) of inflammatory bowel disease were estimated by Poisson distribution.
		                        		
		                        			RESULTS:
		                        			From 2011 to 2020, a total of 1 496 427 permanent residents in Yinzhou District were included, of which 729 996 were male (48.78%). The total follow-up person-years were 8 081 030.82, and the median follow-up person-years were 5.41 [interquartile range (IQR): 5.29]. During the study period, there were 1 217 new cases of inflammatory bowel disease, of which males (624 cases, 51.27%) were more than females (593 cases, 48.73%). The total incidence density was 15.06/100 000 person-years (95%CI: 14.23, 15.93). Among all new cases, there were 1 106 cases (90.88%) of ulcerative colitis, with an incidence density of 13.69 per 100 000 person-years (95%CI: 12.89, 14.52); 70 cases (5.75%) of Crohn's disease, with an incidence density of 0.87 per 100 000 person-years (95%CI: 0.68, 1.09); and 41 cases (3.37%) of indeterminate colitis, with an incidence density of 0.51 per 100 000 person-years (95%CI: 0.36, 0.69). The median age of onset of ulcerative colitis was 50.82 years old (IQR: 18.77), with the highest proportion (15.01%) in the 45-49 years group. The incidence density of ulcerative colitis gradually increased with age, reaching a relatively high level in the 45-49 years group (20.53/100 000 person-years; 95%CI: 17.63, 23.78), followed by a slight increase. And the incidence density in the 65-69 years group was the highest (25.44/100 000 person-years; 95%CI: 20.85, 30.75), with a rapid decrease in the 75-79 years group. The median age of onset of Crohn's disease was 44.34 years (IQR: 33.41), with the highest proportion (12.86%) in the 25-29 years group. Due to the small number of new cases of Crohn's disease, the age distribution fluctuated greatly, with peaks both in young and old people. From 2011 to 2020, the incidence density of inflammatory bowel disease in Yinzhou District was at a low level from 2011 to 2013, and showed a rapid upward trend from 2014 to 2016, reaching a peak of 24.62 per 100 000 person-years in 2016 (95%CI: 21.31, 28.30), and slightly decreased in 2017-2020.
		                        		
		                        			CONCLUSION
		                        			The incidence density of inflammatory bowel disease in Yinzhou District from 2011 to 2020 was at a relatively high level, and medical institutions and health departments need to pay attention to the burden of disease caused by it.
		                        		
		                        		
		                        		
		                        			Adolescent
		                        			;
		                        		
		                        			Adult
		                        			;
		                        		
		                        			Chronic Disease
		                        			;
		                        		
		                        			Colitis, Ulcerative/epidemiology*
		                        			;
		                        		
		                        			Crohn Disease/epidemiology*
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Incidence
		                        			;
		                        		
		                        			Inflammatory Bowel Diseases/epidemiology*
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Middle Aged
		                        			;
		                        		
		                        			Retrospective Studies
		                        			
		                        		
		                        	
2.HucMSC-Ex alleviates inflammatory bowel disease via the lnc78583-mediated miR3202/HOXB13 pathway.
Yuting XU ; Li ZHANG ; Dickson Kofi Wiredu OCANSEY ; Bo WANG ; Yilin HOU ; Rong MEI ; Yongmin YAN ; Xu ZHANG ; Zhaoyang ZHANG ; Fei MAO
Journal of Zhejiang University. Science. B 2022;23(5):423-431
		                        		
		                        			
		                        			As a group of nonspecific inflammatory diseases affecting the intestine, inflammatory bowel disease (IBD) exhibits the characteristics of chronic recurring inflammation, and was proven to be increasing in incidence (Kaplan, 2015). IBD induced by genetic background, environmental changes, immune functions, microbial composition, and toxin exposures (Sasson et al., 2021) primarily includes ulcerative colitis (UC) and Crohn's disease (CD) with complicated clinical symptoms featured by abdominal pain, diarrhea, and even blood in stools (Fan et al., 2021; Huang et al., 2021). UC is mainly limited to the rectum and the colon, while CD usually impacts the terminal ileum and colon in a discontinuous manner (Ordás et al., 2012; Panés and Rimola, 2017). In recent years, many studies have suggested the lack of effective measures in the diagnosis and treatment of IBD, prompting an urgent need for new strategies to understand the mechanisms of and offer promising therapies for IBD.
		                        		
		                        		
		                        		
		                        			Chronic Disease
		                        			;
		                        		
		                        			Colitis, Ulcerative/therapy*
		                        			;
		                        		
		                        			Crohn Disease/epidemiology*
		                        			;
		                        		
		                        			Diarrhea
		                        			;
		                        		
		                        			Homeodomain Proteins
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Inflammatory Bowel Diseases
		                        			;
		                        		
		                        			Mesenchymal Stem Cells/cytology*
		                        			;
		                        		
		                        			MicroRNAs
		                        			;
		                        		
		                        			RNA, Long Noncoding
		                        			;
		                        		
		                        			Recurrence
		                        			;
		                        		
		                        			Umbilical Cord/cytology*
		                        			
		                        		
		                        	
3.Statin Exposure Is Not Associated with Reduced Prevalence of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease.
Shailja C SHAH ; Jason GLASS ; Gennaro GIUSTINO ; Joren R TEN HOVE ; Daniel CASTANEDA ; Joana TORRES ; Akash KUMAR ; Jordan ELMAN ; Thomas A ULLMAN ; Steven H ITZKOWITZ
Gut and Liver 2019;13(1):54-61
		                        		
		                        			
		                        			BACKGROUND/AIMS: Statins have been postulated to lower the risk of colorectal neoplasia. No studies have examined any possible chemopreventive effect of statins in patients with inflammatory bowel disease (IBD) undergoing colorectal cancer (CRC) surveillance. This study examined the association of statin exposure with dysplasia and CRC in patients with IBD undergoing dysplasia surveillance colonoscopies. METHODS: A cohort of patients with IBD undergoing colonoscopic surveillance for dysplasia and CRC at a single academic medical center were studied. The inclusion criteria were IBD involving the colon for 8 years (or any colitis duration if associated with primary sclerosing cholangitis [PSC]) and at least two colonoscopic surveillance exams. The exclusion criteria were CRC or high-grade dysplasia (HGD) prior to or at enrollment, prior colectomy, or limited ( < 30%) colonic disease. The primary outcome was the frequency of dysplasia and/or CRC in statin-exposed versus nonexposed patients. RESULTS: A total of 642 patients met the inclusion criteria (57 statin-exposed and 585 nonexposed). The statin-exposed group had a longer IBD duration, longer follow-up period, and more colonoscopies but lower inflammatory scores, less frequent PSC and less use of thiopurines and biologics. There were no differences in low-grade dysplasia, HGD, or CRC development during the follow-up period between the statin-exposed and nonexposed groups (21.1%, 5.3%, 1.8% vs 19.2%, 2.9%, 2.9%, respectively). Propensity score analysis did not alter the overall findings. CONCLUSIONS: In IBD patients undergoing surveillance colonoscopies, statin use was not associated with reduced dysplasia or CRC rates. The role of statins as chemopreventive agents in IBD remains controversial.
		                        		
		                        		
		                        		
		                        			Academic Medical Centers
		                        			;
		                        		
		                        			Biological Products
		                        			;
		                        		
		                        			Chemoprevention
		                        			;
		                        		
		                        			Cholangitis, Sclerosing
		                        			;
		                        		
		                        			Cohort Studies
		                        			;
		                        		
		                        			Colectomy
		                        			;
		                        		
		                        			Colitis
		                        			;
		                        		
		                        			Colon
		                        			;
		                        		
		                        			Colonic Diseases
		                        			;
		                        		
		                        			Colonoscopy
		                        			;
		                        		
		                        			Colorectal Neoplasms
		                        			;
		                        		
		                        			Epidemiology
		                        			;
		                        		
		                        			Follow-Up Studies
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Hydroxymethylglutaryl-CoA Reductase Inhibitors*
		                        			;
		                        		
		                        			Inflammatory Bowel Diseases*
		                        			;
		                        		
		                        			Prevalence*
		                        			;
		                        		
		                        			Propensity Score
		                        			
		                        		
		                        	
4.Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries.
Taku KOBAYASHI ; Tadakazu HISAMATSU ; Yasuo SUZUKI ; Haruhiko OGATA ; Akira ANDOH ; Toshimitsu ARAKI ; Ryota HOKARI ; Hideki IIJIMA ; Hiroki IKEUCHI ; Yoh ISHIGURO ; Shingo KATO ; Reiko KUNISAKI ; Takayuki MATSUMOTO ; Satoshi MOTOYA ; Masakazu NAGAHORI ; Shiro NAKAMURA ; Hiroshi NAKASE ; Tomoyuki TSUJIKAWA ; Makoto SASAKI ; Kaoru YOKOYAMA ; Naoki YOSHIMURA ; Kenji WATANABE ; Miiko KATAFUCHI ; Mamoru WATANABE ; Toshifumi HIBI
Intestinal Research 2018;16(2):168-177
		                        		
		                        			
		                        			Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease of the gastrointestinal tract, with increasing prevalence worldwide. IBD Ahead is an international educational program that aims to explore questions commonly raised by clinicians about various areas of IBD care and to consolidate available published evidence and expert opinion into a consensus for the optimization of IBD management. Given differences in the epidemiology, clinical and genetic characteristics, management, and prognosis of IBD between patients in Japan and the rest of the world, this statement was formulated as the result of literature reviews and discussions among Japanese experts as part of the IBD Ahead program to consolidate statements of factors for disease prognosis in IBD. Evidence levels were assigned to summary statements in the following categories: disease progression in CD and UC; surgery, hospitalization, intestinal failure, and permanent stoma in CD; acute severe UC; colectomy in UC; and colorectal carcinoma and dysplasia in IBD. The goal is that this statement can aid in the optimization of the treatment strategy for Japanese patients with IBD and help identify high-risk patients that require early intervention, to provide a better long-term prognosis in these patients.
		                        		
		                        		
		                        		
		                        			Asian Continental Ancestry Group
		                        			;
		                        		
		                        			Colectomy
		                        			;
		                        		
		                        			Colitis, Ulcerative
		                        			;
		                        		
		                        			Colorectal Neoplasms
		                        			;
		                        		
		                        			Consensus
		                        			;
		                        		
		                        			Crohn Disease
		                        			;
		                        		
		                        			Disease Management*
		                        			;
		                        		
		                        			Disease Progression
		                        			;
		                        		
		                        			Early Intervention (Education)
		                        			;
		                        		
		                        			Epidemiology
		                        			;
		                        		
		                        			Expert Testimony
		                        			;
		                        		
		                        			Gastrointestinal Tract
		                        			;
		                        		
		                        			Hospitalization
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Inflammatory Bowel Diseases*
		                        			;
		                        		
		                        			Japan*
		                        			;
		                        		
		                        			Prevalence
		                        			;
		                        		
		                        			Prognosis
		                        			
		                        		
		                        	
5.Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy–Access to Rapid Treatment (iSTART) approach.
Silvio DANESE ; Rupa BANERJEE ; JR Fraser CUMMINGS ; Iris DOTAN ; Paulo G KOTZE ; Rupert Wing Loong LEONG ; Kristine PARIDAENS ; Laurent PEYRIN-BIROULET ; Glyn SCOTT ; Gert Van ASSCHE ; Jan WEHKAMP ; Jesús K YAMAMOTO-FURUSHO
Intestinal Research 2018;16(4):522-528
		                        		
		                        			
		                        			Symptomatic ulcerative colitis (UC) can be a chronic, disabling condition. Flares in disease activity are associated with many of the negative impacts of mild-to-moderate UC. Rapid resolution of flares can provide benefits to patients and healthcare systems. i Support Therapy–Access to Rapid Treatment (iSTART) introduces patient-centered care for mild-to-moderate UC. iSTART provides patients with the ability to self-assess symptomology and self-start a short course of second-line treatment when necessary. An international panel of experts produced consensus statements and recommendations. These were informed by evidence from systematic reviews on the epidemiology, mesalazine (5-ASA) treatment, and patient use criteria for second-line therapy in UC. Optimized 5-ASA is the first-line treatment in all clinical guidelines, but may not be sufficient to induce remission in all patients. Corticosteroids should be prescribed as second-line therapy when needed, with budesonide MMX® being a preferred steroid option. Active involvement of suitable patients in management of UC flares has the potential to improve therapy, with patients able to show good accuracy for flare self-assessment using validated tools. There is a place in the UC treatment pathway for an approach such as iSTART, which has the potential to provide patient, clinical and economic benefits.
		                        		
		                        		
		                        		
		                        			Adrenal Cortex Hormones
		                        			;
		                        		
		                        			Budesonide
		                        			;
		                        		
		                        			Colitis, Ulcerative*
		                        			;
		                        		
		                        			Consensus*
		                        			;
		                        		
		                        			Delivery of Health Care
		                        			;
		                        		
		                        			Epidemiology
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Mesalamine
		                        			;
		                        		
		                        			Patient-Centered Care
		                        			;
		                        		
		                        			Self-Assessment
		                        			;
		                        		
		                        			Ulcer*
		                        			
		                        		
		                        	
6.Changing epidemiological trends of inflammatory bowel disease in Asia.
Wee Khoon NG ; Sunny H WONG ; Siew C NG
Intestinal Research 2016;14(2):111-119
		                        		
		                        			
		                        			Inflammatory bowel disease (IBD) has become more common in Asia over the past few decades. The rate of increase in prevalence of the disease varies greatly in Asia, with several countries in East Asia experiencing a more than doubled increase in IBD prevalence over the past decade. Historically, ulcerative colitis (UC) is more common than Crohn's disease (CD) in Asia. However, a reverse trend is beginning to appear in more developed countries in Asia such as Japan, Korea, and Hong Kong. While Asian IBD patients share many similarities with their Western counterparts, there are important differences with significant clinical implications. In Asia, there are more men with CD, more ileo-colonic involvement in CD, less familial aggregation, fewer extra-intestinal manifestations and worse clinical outcomes for older-onset patients with UC. These differences are likely related to the different genetic makeup and environmental exposures in different regions. Evaluation of the differences and rates in epidemiologic trends may help researchers and clinicians estimate disease burden and understand the reasons behind these differences, which may hold the key to unravel the etiology of IBD.
		                        		
		                        		
		                        		
		                        			Asia*
		                        			;
		                        		
		                        			Asian Continental Ancestry Group
		                        			;
		                        		
		                        			Colitis, Ulcerative
		                        			;
		                        		
		                        			Crohn Disease
		                        			;
		                        		
		                        			Developed Countries
		                        			;
		                        		
		                        			Environmental Exposure
		                        			;
		                        		
		                        			Epidemiology
		                        			;
		                        		
		                        			Far East
		                        			;
		                        		
		                        			Hong Kong
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Inflammatory Bowel Diseases*
		                        			;
		                        		
		                        			Japan
		                        			;
		                        		
		                        			Korea
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Prevalence
		                        			
		                        		
		                        	
7.What's the Clinical Features of Colitis in Elderly People in Long-Term Care Facilities?.
So Yoon YOON ; Sung Ae JUNG ; Sun Kyung NA ; Jae In RYU ; Hye Won YUN ; Min Jin LEE ; Eun Mi SONG ; Seong Eun KIM ; Hye Kyung JUNG ; Ki Nam SHIM
Intestinal Research 2015;13(2):128-134
		                        		
		                        			
		                        			BACKGROUND/AIMS: As life expectancy has increased, the number of elderly patients who need long-term care has grown rapidly. Mortality in patients with colitis in long-term care facilities (LTCFs) is increasing. We intend to investigate the main causes of colitis in LTCFs compared to those of colitis in local communities, and to identify the clinical features and risk factors of patients with colitis in LTCFs. METHODS: We retrospectively analyzed epidemiology, medical conditions, laboratory values, diagnoses, and clinical courses of elderly patients aged > or =65 who were admitted to the Ewha Womans University hospital with colitis between January 2007 and July 2012. RESULTS: Patients with colitis in LTCFs (n=20) were compared with elderly patients with colitis in local communities (n=154). Fifty-five percent of colitis in LTCFs was caused by Clostridium difficile infection (CDI), 30% was due to ischemic colitis, and 15% was due to non-specific colitis. Non-specific colitis was the most common (63%) in the community group. Clinical outcomes were also significantly different between both groups: higher mortality (10.0% vs. 0.64%, P=0.021), higher requirement for intensive care units care (50.0% vs. 18.8%, P<0.01) in LTCFs group. In univariate analysis, the most significant risk factor for death in patients in LTCFs was decreased mental faculties. CONCLUSIONS: Patients in LTCFs showed worse clinical outcomes and a much higher prevalence of CDI compared to patients from local communities. We suggest early and active evaluation, such as endoscopic examination, for differential diagnosis in patients in LTCFs.
		                        		
		                        		
		                        		
		                        			Aged*
		                        			;
		                        		
		                        			Clostridium difficile
		                        			;
		                        		
		                        			Colitis*
		                        			;
		                        		
		                        			Colitis, Ischemic
		                        			;
		                        		
		                        			Diagnosis
		                        			;
		                        		
		                        			Diagnosis, Differential
		                        			;
		                        		
		                        			Epidemiology
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Intensive Care Units
		                        			;
		                        		
		                        			Life Expectancy
		                        			;
		                        		
		                        			Long-Term Care*
		                        			;
		                        		
		                        			Mortality
		                        			;
		                        		
		                        			Prevalence
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Risk Factors
		                        			
		                        		
		                        	
8.What's the Clinical Features of Colitis in Elderly People in Long-Term Care Facilities?.
So Yoon YOON ; Sung Ae JUNG ; Sun Kyung NA ; Jae In RYU ; Hye Won YUN ; Min Jin LEE ; Eun Mi SONG ; Seong Eun KIM ; Hye Kyung JUNG ; Ki Nam SHIM
Intestinal Research 2015;13(2):128-134
		                        		
		                        			
		                        			BACKGROUND/AIMS: As life expectancy has increased, the number of elderly patients who need long-term care has grown rapidly. Mortality in patients with colitis in long-term care facilities (LTCFs) is increasing. We intend to investigate the main causes of colitis in LTCFs compared to those of colitis in local communities, and to identify the clinical features and risk factors of patients with colitis in LTCFs. METHODS: We retrospectively analyzed epidemiology, medical conditions, laboratory values, diagnoses, and clinical courses of elderly patients aged > or =65 who were admitted to the Ewha Womans University hospital with colitis between January 2007 and July 2012. RESULTS: Patients with colitis in LTCFs (n=20) were compared with elderly patients with colitis in local communities (n=154). Fifty-five percent of colitis in LTCFs was caused by Clostridium difficile infection (CDI), 30% was due to ischemic colitis, and 15% was due to non-specific colitis. Non-specific colitis was the most common (63%) in the community group. Clinical outcomes were also significantly different between both groups: higher mortality (10.0% vs. 0.64%, P=0.021), higher requirement for intensive care units care (50.0% vs. 18.8%, P<0.01) in LTCFs group. In univariate analysis, the most significant risk factor for death in patients in LTCFs was decreased mental faculties. CONCLUSIONS: Patients in LTCFs showed worse clinical outcomes and a much higher prevalence of CDI compared to patients from local communities. We suggest early and active evaluation, such as endoscopic examination, for differential diagnosis in patients in LTCFs.
		                        		
		                        		
		                        		
		                        			Aged*
		                        			;
		                        		
		                        			Clostridium difficile
		                        			;
		                        		
		                        			Colitis*
		                        			;
		                        		
		                        			Colitis, Ischemic
		                        			;
		                        		
		                        			Diagnosis
		                        			;
		                        		
		                        			Diagnosis, Differential
		                        			;
		                        		
		                        			Epidemiology
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Intensive Care Units
		                        			;
		                        		
		                        			Life Expectancy
		                        			;
		                        		
		                        			Long-Term Care*
		                        			;
		                        		
		                        			Mortality
		                        			;
		                        		
		                        			Prevalence
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Risk Factors
		                        			
		                        		
		                        	
9.Assessment of age in ulcerative colitis patients with ileal pouch creation - an evaluation of outcomes.
Ker Kan TAN ; Ragavan MANOHARAN ; Saissan RAJENDRAN ; Praveen RAVINDRAN ; Christopher J YOUNG
Annals of the Academy of Medicine, Singapore 2015;44(3):92-97
INTRODUCTIONThe aim of the study was to determine if age at the creation of an ileal pouchanal anastomosis (IPAA) has an impact on the outcomes in patients with ulcerative colitis (UC).
MATERIALS AND METHODSA retrospective review of all patients who underwent IPAA for UC from 1999 to 2011 was performed. Long-term functional outcome was assessed using both the Cleveland Clinic and St Mark's incontinence scores.
RESULTSEighty-nine patients, with a median age of 46 (range, 16 to 71) years, formed the study group. The median duration of disease prior to their pouch surgery was 7 (0.5 to 39) years. There were 57 (64%) patients who were aged ≤50 years old and 32 (36%) who were >50 years old. Fifty-seven (64%) patients developed perioperative complications of which 51 (89.5%) were minor. High ileostomy output (n = 21, 23.6%) and urinary symptoms (n = 13, 14.6%) were the most commonly encountered complications. The older patients were more likely to have an ASA score ≥3 and a longer length of stay. Although there was a higher incidence of complications in the older group of patients, the difference was not statistically significant. There were no significant differences in the incidence of severe complications. Forty-nine (55%) patients completed our questionnaire on the evaluation of their functional outcomes. There were no significant differences in the Cleveland Clinic and St Mark's incontinence scores between the older (n = 19, 38.8%) and younger (n = 30, 61.2%) patients. There were also no significant differences in the frequency of bowel movements during the day or overnight after sleep between the 2 groups.
CONCLUSIONIPAA procedure for patients with UC can be safely performed. Long-term functional outcome is not significantly influenced by the age at which the IPAA was created.
Adolescent ; Adult ; Age Factors ; Aged ; Colitis, Ulcerative ; surgery ; Colonic Pouches ; Fecal Incontinence ; diagnosis ; epidemiology ; etiology ; Female ; Follow-Up Studies ; Humans ; Incidence ; Male ; Middle Aged ; Postoperative Complications ; diagnosis ; epidemiology ; Proctocolectomy, Restorative ; Retrospective Studies ; Treatment Outcome ; Young Adult
10.Characteristics of Pediatric Inflammatory Bowel Disease in Korea: Comparison with EUROKIDS Data.
Hyeon Ah LEE ; Jung Yoon SUK ; Sung Youn CHOI ; Eun Ran KIM ; Young Ho KIM ; Chang Kyun LEE ; Kyu Chan HUH ; Kang Moon LEE ; Dong Il PARK
Gut and Liver 2015;9(6):756-760
		                        		
		                        			
		                        			BACKGROUND/AIMS: Pediatric inflammatory bowel disease (IBD) has been increasing worldwide. The characteristics of pediatric-onset IBD have mainly been reported in Western countries. We investigated the clinical characteristics of pediatric IBD in Korea and compared these with the data from the 5-year European multicenter study of children with new-onset IBD (EUROKIDS registry). METHODS: Children who were diagnosed with IBD between July 1987 and January 2012 were investigated at five Korean university hospitals. Their clinical characteristics were retrospectively evaluated by medical record review. The results were compared with the EUROKIDS data. RESULTS: A total of 30 children with Crohn's disease (CD) and 33 children with ulcerative colitis (UC) were enrolled. In comparison with the EUROKIDS group, Korean pediatric IBD patients showed a male predominance (86.7% vs 59.2%, p=0.002 in CD; 75.8% vs 50%, p=0.003 in UC). Korean pediatric CD patients had a higher prevalence of terminal ileal disease (36.7% vs 16.3%, p=0.004) and perianal disease (33.3% vs 8.2%, p<0.001) than patients in the EUROKIDS group. Korean pediatric UC patients had a higher prevalence of proctitis than patients in the EUROKIDS group. CONCLUSIONS: Our results suggest that the characteristics of Korean pediatric IBD patients and European pediatric IBD patients may be different.
		                        		
		                        		
		                        		
		                        			Adolescent
		                        			;
		                        		
		                        			Anus Diseases/complications/epidemiology/pathology
		                        			;
		                        		
		                        			Child
		                        			;
		                        		
		                        			Colitis, Ulcerative/complications/epidemiology/*pathology
		                        			;
		                        		
		                        			Crohn Disease/complications/epidemiology/*pathology
		                        			;
		                        		
		                        			Europe/epidemiology
		                        			;
		                        		
		                        			Female
		                        			;
		                        		
		                        			Humans
		                        			;
		                        		
		                        			Ileal Diseases/complications/epidemiology/pathology
		                        			;
		                        		
		                        			Male
		                        			;
		                        		
		                        			Prevalence
		                        			;
		                        		
		                        			Proctitis/epidemiology/etiology
		                        			;
		                        		
		                        			Registries
		                        			;
		                        		
		                        			Republic of Korea/epidemiology
		                        			;
		                        		
		                        			Retrospective Studies
		                        			;
		                        		
		                        			Sex Factors
		                        			
		                        		
		                        	
            
Result Analysis
Print
Save
E-mail